ISU Abxis Co., Ltd. (KOSDAQ:086890)
4,440.00
-200.00 (-4.31%)
At close: Apr 2, 2026
ISU Abxis Revenue
In the year 2025, ISU Abxis had annual revenue of 56.67B KRW, down -5.95%. ISU Abxis had revenue of 10.93B in the quarter ending December 31, 2025, a decrease of -47.06%.
Revenue
56.67B
Revenue Growth
-5.95%
P/S Ratio
3.19
Revenue / Employee
318.38M
Employees
178
Market Cap
180.81B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | -3.59B | -5.95% |
| Dec 31, 2024 | 60.26B | 5.95B | 10.96% |
| Dec 31, 2023 | 54.31B | 13.14B | 31.91% |
| Dec 31, 2022 | 41.17B | 13.15B | 46.94% |
| Dec 31, 2021 | 28.02B | 2.41B | 9.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 69.29B |
| Genome & Company | 24.59B |
| Prestige Biologics | 19.24B |
| BIO-FD&C | 18.82B |
| QuadMedicine | 13.11B |
| Kangstem Biotech | 12.77B |
| Bio Solution | 8.27B |
| NovMetaPharma | 1.30B |